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Summary. We investigated the effeet of sodium val-
proatc on plasma ACTH and serum cortisol eon-
centrations in different pathological states of 
ACTH hypersecretion. Five patients with pituitary 
dependent Cushing's syndrome, two patients with 
Nelson's syndrome and five patients with Add-
ison's disease were studied. Neither a single dose 
nor long term administration of sodium valproate 
resulted in a significant decrease of plasma ACTH 
levels in patients with Cushing's disease and Nel-
son's syndrome. Furthermore, the response of 
ACTH and cortisol to stimulation with lysine-va-
sopressin was unaffected during acute and chronie 
treatment. Patients with Addison's disease showed 
a slight attenuation of the ACTH response to ly-
sine-vasopressin as compared to placebo but the 
difference was not statistically significant. In con-
c1usion: sodium valproate does not appear to be 
effective in controlling ACTH hypersecretion in pi-
tuitary dependent Cushing's syndrome. 
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Within the past decade selective transsphenoidal 
microsurgery has become weIl established as an 
effective treatment of pituitary dependent Cush-
ing's syndrome [12]. However, if surgery fails to 
correct ACTH hypersecretion treatment with adre-
nal blocking agents or neuropharmacological 
agents is indicated [12]. In recent years sodium val-
proate, an anticonvulsant, has been shown to de-
crease plasma ACTH levels in Nelson's syndrome 
[5,6,9]. However, the efficacy of sodium valproate 
Abbreviations: ACTH = Adrenocorticotrophic hormone; CRF = 
Corticotropin releasing factor 
in pituitary dependent Cushing's syndrome re-
mains controversial [1, 3, 4, 6, 10, 11, 13]. This 
study evaluates the effectiveness of sodium val-
proate in different ACTH hypersecreting states 
and investigates the site of its action. 
Patients and Methods 
Five patients with pituitary dependent Cushing's 
syndrome, two patients with Nelson's syndrome 
and five patients with patients Addison's disease 
were studied. 
Two of the patients with Cushing's disease had 
undergone bilateral adrenalectomy. In one ofthem 
was evidence of residual adrenal function from an 
adrenal remnant. 
All patients received placebo on day one and 
300 mg sodium valproate orallyon day two at 
9.00 a.m. Blood sampies were eollected for plasma 
ACTH and serum cortisol hourly between 
9.00 a.m. and 1.00 p.m. 
At 1.00 p.m. a lysine-vasopressin test was per-
formed (5 IU vasopressin as a continuous infusion 
over 60 min). Blood sampies were collected for cor-
tisol and ACTH at 0, 15, 30, 45, 60 and 90 min 
after the start of the infusion. 
In patients with Cushing's disease and Nelson's 
syndrome the effect of a long term treatment with 
sodium valproate was also evaluated. After day 2 
the patients received 300 mg sodium valproate 
twice a day for four weeks. After four weeks collec-
tion of blood sampies and lysine-vasopressin test-
ing was performed as on day 1. 
Plasma ACTH was measured bei RIA [2] after 
extraction with QUSO [16]. 
Serum cortisol was determined by standard 
RIA techniques using commercially available re-
agents (NEN, Dreieich, FRG). All sampies from 
each subject were analysed in the same assay. Sta-
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Fig. 1. Effect of sodium valproate on baseline 
plasma ACTH and serum cortisol concentrations in 
5 patients with Cushing's disease 
9 10 11 12 9 10 11 12 
time 
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tistical analysis of the data was performed using 
Studenfs test for paired data. 
Results 
In none of the patients with Cushing's disease the 
ACTH and cortisollevels decreased after a single 
dose or after long term treatment with sodium val-
proate (Fig. 1). 
In addition, the increase in the ACTH and cor-
tisol concentrations in response to lysine-vasopres-
sin administration was not attenuated by acute or 
chronic administration of sodium valproate as 
compared to placebo (Fig. 2). 
In Nelson's syndrome we observed no effect 
on the baseline ACTH levels both during single 
dose and chronic sodium valproate administration. 
Furthermore no difference was found in the re-
sponse of ACTH to lysine-vasopressin. 
In Addison's disease the average rise of the 
plasma ACTH concentration in response to lysine-
vasopressin after placebo was low (Fig. 3). After 
a single dose of sodium valproate an even lower 
response was found. However, this difference was 
not significant. 
Discussion 
Sodium valproate is a gamma-amino-butyric acid 
(GABA) transaminase inhibitor and raises GABA 
levels in the hypothalamus [14]. GABA, an inhibi-
tory neurotransmitter, has been implicated in the 
control of CRF secretion from the hypothalamus 
[8]. Therefore it has been expected that sodium 
valproate may lower ACTH levels in Nelson's syn-
drome and Cushing's disease by increasing GABA 
levels in the hypothalamus and thus by inhibition 
of the CRF drive on the pituitary. In fact, in most 
patients with Nelson's syndrome sodium valproate 
has been reported to be effective in lowering plas-
ma ACTH levels [5, 6, 9]. However, the results 
in pituitary dependent Cushing's syndrome are 
controversial. In our patients with active Cushing's 
disease plasma ACTH and serum cortisol levels 
did not decrease with single dose or long term 
treatment. This is similar to the experience of Loli 
et al. [13] and Ambrosi et a1. [3]. However, clinical 
remission in Cushing's disease induced by sodium 
valproate has been reported occasionally [4, 10, 
11] but these cases appear to be very rare. These 
inconsistend results may be explained by the fact 
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Fig.2. Plasma ACTH and serum cortisollevels 
(baseline value = 100%) in response to lysine-
vaspressin after placebo, after a single dose of 
sodium valproate and after long term treatment in 
5 patients with Cushing's disease 
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Fig. 3. Plasma A CTH levels (baseline value = 100 %) in response 
to lysine-vasopressin after pretreatment with placebo (0-0) 
and with 300 mg sodium valproate (.-.) in 5 patients with 
Addison's disease 
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that in Cushing's disease the underlying dis order 
appears to be heterogenous. A hypothalamic origin 
with excessive CRF production resulting in ACTH 
hypersecretion has been postulated [15] but it 
seems to be a rare cause of Cushing's disease. The 
results of pituitary microsurgery are more in fa-
vour of a primary pituitary disease, since in most 
instances corticotropic adenomas can be removed 
[12]. However, even these micro- or macroadeno-
mas seem to be heterogenous in nature [12] which 
might contribute to the heterogenous response pat-
tern to sodium valproate in Cushing's disease. 
Besides the hypothalamus GABA and its bind-
ing sites are also present in the human pituitary 
[7] indicating the possibility of a direct action of 
GABA on the pituitary. Nevertheless the present 
data, if at all, argues rather for a suprahypophyseal 
site of action. We found no significant inhibition 
of the ACTH response to lysine-vasopressin in pa-
tients with Addison's disease in whom generally 
the ACTH release is assumed to be sensitive to 
inhibitory agents. In case of a direct action on the 
anterior pituitary, a marked attenuation of the 
ACTH response to stimulation with lysine-vaso-
pressin may be expected. 
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